Sign in
ALPN Stock Price, Chart, Stats & News
Alpine Immune Sciences, Inc.
Save
4.46B
Market cap
–
Current P/E
–
Forward P/E
ALPN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -37.41% |
Operating margin | -75.16% |
Pretax margin | -54.49% |
Net margin | -54.66% |
Effective tax rate | -0.32% |
ROA | -8.47% |
ROE | -12.69% |
D/E | 0.03x |
Interest coverage ratio | -451.53x |
ALPN valuation
P/E | – |
P/S | 75.70x |
P/B | 9.91x |
P/CF | -41.11x |
P/FCF | -56.06x |
P/OCF | -41.11x |
PEG | -1.01x |
EV multiple | -142.99x |
About
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions.
Similar securities
Based on sector and market capitalization
Report issue